Tepezza vs Izervay
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Tepezza | US Izervay | |
|---|---|---|
| Generic name | teprotumumab | avacincaptad pegol |
| Drug class | IGF-1R Inhibitor (Biologic) | Complement C5 Inhibitor |
| Treats | Thyroid eye disease | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | Amgen | Astellas Pharma |
| Year approved | 2020 | 2023 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Muscle spasms, Nausea, Hair loss, Hearing problems | Bleeding in the eye, Increased eye pressure, Floaters, Risk of eye infection |
Frequently asked questions
Is Tepezza or Izervay better?
Neither is universally "better." Tepezza (teprotumumab) and Izervay (avacincaptad pegol) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Tepezza and Izervay?
Tepezza is a IGF-1R Inhibitor (Biologic) made by Amgen, while Izervay is a Complement C5 Inhibitor made by Astellas Pharma. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Tepezza has the larger estimated TV advertising budget of the two.